These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21307145)

  • 1. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
    De Luisi A; Ferrucci A; Coluccia AM; Ria R; Moschetta M; de Luca E; Pieroni L; Maffia M; Urbani A; Di Pietro G; Guarini A; Ranieri G; Ditonno P; Berardi S; Caivano A; Basile A; Cascavilla N; Capalbo S; Quarta G; Dammacco F; Ribatti D; Vacca A
    Clin Cancer Res; 2011 Apr; 17(7):1935-46. PubMed ID: 21307145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
    Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
    Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
    Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
    Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets.
    Berardi S; Caivano A; Ria R; Nico B; Savino R; Terracciano R; De Tullio G; Ferrucci A; De Luisi A; Moschetta M; Mangialardi G; Catacchio I; Basile A; Guarini A; Zito A; Ditonno P; Musto P; Dammacco F; Ribatti D; Vacca A
    Oncogene; 2012 May; 31(18):2258-69. PubMed ID: 21963844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
    Vacca A; Scavelli C; Montefusco V; Di Pietro G; Neri A; Mattioli M; Bicciato S; Nico B; Ribatti D; Dammacco F; Corradini P
    J Clin Oncol; 2005 Aug; 23(23):5334-46. PubMed ID: 15939924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
    Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
    Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
    Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
    Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
    Guo HM; Sun L; Yang L; Liu XJ; Nie ZY; Luo JM
    Oncol Rep; 2018 Jun; 39(6):2873-2880. PubMed ID: 29693175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma.
    Lamanuzzi A; Saltarella I; Frassanito MA; Ribatti D; Melaccio A; Desantis V; Solimando AG; Ria R; Vacca A
    Am J Pathol; 2021 Apr; 191(4):748-758. PubMed ID: 33516787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?
    Saltarella I; Frassanito MA; Lamanuzzi A; Brevi A; Leone P; Desantis V; Di Marzo L; Bellone M; Derudas D; Ribatti D; Chiaramonte R; Palano MT; Neri A; Mariggiò MA; Fumarulo R; Dammacco F; Racanelli V; Vacca A; Ria R
    Neoplasia; 2019 Jan; 21(1):93-105. PubMed ID: 30529074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.
    Ria R; Todoerti K; Berardi S; Coluccia AM; De Luisi A; Mattioli M; Ronchetti D; Morabito F; Guarini A; Petrucci MT; Dammacco F; Ribatti D; Neri A; Vacca A
    Clin Cancer Res; 2009 Sep; 15(17):5369-78. PubMed ID: 19690192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
    Xu HY; Pan YM; Chen ZW; Lin Y; Wang LH; Chen YH; Jie TT; Lu YY; Liu JC
    J Ethnopharmacol; 2013 Apr; 146(3):724-33. PubMed ID: 23434607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
    Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma.
    Ria R; Vacca A; Russo F; Cirulli T; Massaia M; Tosi P; Cavo M; Guidolin D; Ribatti D; Dammacco F
    Thromb Haemost; 2004 Dec; 92(6):1438-45. PubMed ID: 15583754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-angiogenic activity of carebastine: a plausible mechanism affecting airway remodelling.
    De Luisi A; Mangialardi G; Ria R; Acuto G; Ribatti D; Vacca A
    Eur Respir J; 2009 Oct; 34(4):958-66. PubMed ID: 19357149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of alpha-tocopherol ether-linked acetic acid in VEGF-induced angiogenesis and the possible mechanisms in human umbilical vein endothelial cells.
    Chuang CH; Liu CH; Lu TJ; Hu ML
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):310-6. PubMed ID: 25447407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
    Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.